Skip to Content

Acrux Ltd ARUXF Stock Quote

| Rating as of


Last close prices updated as of Mar 31, 2023, 9:30 AM EST | USD
  • Last Close 0.04
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 0.04  –  0.04
  • Year Range 0.03  –  0.08
  • Market Cap 12.4158 Mil
  • Volume / Avg 800.0 /  900.0
  • Price / Sales 10.99
  • Price / Book 3.20
  • Forward Div Yield
  • Trailing Div Yield 197.95%

Morningstar‘s Stock Analysis ARUXF

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ARUXF

Company Profile ARUXF

Business Description

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products which administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution and among others.

103-113 Stanley Street, West Melbourne
Melbourne, VIC, 3003, AUS
Industry Biotechnology
Employees 36

Competitors & Peers ARUXF

Morningstar does not cover competitors or peers for this firm.

FAQs for Acrux Ltd Stock

No. ARUXF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ARUXF’s market cap is 12.42 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ARUXF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ARUXF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ARUXF’s historical performance against its industry peers and the overall market.